PRO CAR-202
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
PreclinicalActive
Key Facts
Indication
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Phase
Preclinical
Status
Active
Company
About PromiCell
PromiCell is a clinical-stage biotech company developing next-generation CAR-T and TCR therapies for cancer, with a focus on addressing the limitations of current treatments. Its core technological innovations include IL-18 cytokine armoring to overcome tumor resistance and a hypoxic manufacturing process to enhance cell durability. The company's pipeline, sourced from Fred Hutchinson Cancer Center and Memorial Sloan Kettering, targets high-need areas like metastatic prostate cancer, leukemia, and sarcoma, with two ongoing clinical trials and several more planned for 2026.
View full company profileTherapeutic Areas
Other Metastatic Castration-Resistant Prostate Cancer (mCRPC) Drugs
| Drug | Company | Phase |
|---|---|---|
| Tomivosertib | eFFECTOR Therapeutics | Phase 2 |
| Gedatolisib + Darolutamide | Celcuity | Phase 1b/3 |
| SNP-101 (estimated) | SmartNuclide Biopharma | Phase 1 |
| AB001 (²¹²Pb-NG001) | ARTBIO | Phase 1/2 |
| AB-3028 | Arsenal Biosciences | IND-Enabling |
| PRO CAR-201A | PromiCell | Phase 1 |
| FG-3246 | Kyntra Bio | Phase 2 |
| PROVENGE (sipuleucel-T) | Dendreon | Approved |
| RP12146 | Rhizen Pharmaceuticals | Phase 1b |
| Monoclonal Antibody (undisclosed) | MetaCurUm Biotech | Preclinical |
| ModraDoc006/r | Modra Pharmaceuticals | Phase 2b |
| SYNC-T | Syncromune | Phase 2 |